Drugs / lestaurtinib
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00084422 | Aug 2003 → Sep 2009 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00668421 | Apr 2008 → Sep 2013 | acquired polycythemia vera, essential thrombocythemia, myelofibrosis | Ronald Hoffman | Unknown | No outcome recorded |
| Phase 1/2 | NCT00469859 | Jun 2007 → Mar 2010 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT00586651 | Dec 2007 → Oct 2009 | acquired polycythemia vera, essential thrombocythemia | Cephalon | Completed | Missed primary |
| Phase 2 | NCT00494585 | Jun 2007 → May 2010 | leukemia, myelofibrosis | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00242827 | Apr 2006 → May 2007 | plasma cell myeloma | Cephalon | Terminated | No outcome recorded |
| Phase 2 | NCT00236119 | Jun 2005 → Oct 2007 | psoriasis | Cephalon | Completed | No outcome recorded |
| Phase 2 | NCT00081601 | Mar 2004 → May 2005 | prostate cancer | Cephalon | Completed | No outcome recorded |
| Phase 2 | NCT00030186 | Jan 2002 → Feb 2003 | acute myeloid leukemia | Cephalon | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00557193 | Jan 2008 → Sep 2017 | T-cell childhood acute lymphocytic leukemia, acute undifferentiated leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00079482 Comparator | Oct 2003 → Mar 2009 | acute myeloid leukemia | Cephalon | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-06-14 | Sequella, Inc. | Results Woman CEO's Proving Glass Ceiling Can be Broken sequella.com ↗
An analysis of the study showed that patients who received lestaurtinib showed similar rates of complete response but no added survival benefit. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-06-14 | Sequella, Inc. | Woman CEO's Proving Glass Ceiling Can be Broken sequella.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lestaurtinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00469859 ↗ |
| Known as | A-154475 | ChEMBL registry synonym — accepted as the source's own label CHEMBL603469 ↗ |
| Known as | A-154475.0 | ChEMBL registry synonym — accepted as the source's own label CHEMBL603469 ↗ |
| Known as | CEP-701 | “Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.” PMID 24903629 ↗ Oct 20137“Lestaurtinib (CEP-701), oral formulation.” NCT00668421 ↗ |
| Known as | KT-555 | ChEMBL registry synonym — accepted as the source's own label CHEMBL603469 ↗ |
| Known as | KT-5555 | ChEMBL registry synonym — accepted as the source's own label CHEMBL603469 ↗ |
| Known as | NSC#617807 | “A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3...” NCT00557193 ↗ |
| Known as | SP-924 | ChEMBL registry synonym — accepted as the source's own label CHEMBL603469 ↗ |
| Known as | SPM-924 | ChEMBL registry synonym — accepted as the source's own label CHEMBL603469 ↗ |
| Action | Inhibit | “CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vivo experiments.” PMID 20008298 ↗ Dec 20094“Neurotrophic tyrosine kinase receptor type 2 inhibitor” CHEMBL603469 ↗ “Tyrosine-protein kinase receptor RET inhibitor” CHEMBL603469 ↗ “Nerve growth factor receptor Trk-A inhibitor” CHEMBL603469 ↗ “NT-3 growth factor receptor inhibitor” CHEMBL603469 ↗ |
| Modality | Small molecule | — CHEMBL603469 ↗ |
| Route | Oral | “Patients who meet eligibility criteria will be enrolled at a dosage of 60 mg orally 2 times a day for 28 days (1 cycle).” NCT00030186 ↗ |
| Target | JAK2 | “CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vivo experiments.” PMID 20008298 ↗ Dec 2009 |
| Target | NTRK1 | “Nerve growth factor receptor Trk-A inhibitor” CHEMBL603469 ↗ |
| Target | NTRK2 | “Neurotrophic tyrosine kinase receptor type 2 inhibitor” CHEMBL603469 ↗ |
| Target | NTRK3 | “NT-3 growth factor receptor inhibitor” CHEMBL603469 ↗ |
| Target | RET | “Tyrosine-protein kinase receptor RET inhibitor” CHEMBL603469 ↗ |